Wandercraft·· 2025-11-03AI score54
Wandercraft Atalante X wins second FDA indication expansion, covering C4-L5 spinal cord injury and multiple sclerosis patients
Summary
Wandercraft announced that its self-balancing exoskeleton Atalante X has received FDA indication expansion clearance, extending its scope from T5-L5 to C4-L5 spinal cord injury and adding a new indication for multiple sclerosis.
This page provides a summary and source link only. Read the full article at the source.
Source: Wandercraft · wandercraft.eu